Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring for people living with heart failure.
Astellas has licensed rights to a smart stethoscope device developed by Eko Health, that it will use as part of a digital therapeutic (DTx) approach to heart failure.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.